Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Large Decrease in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 149,731 shares, a decrease of 27.4% from the January 29th total of 206,238 shares. Based on an average trading volume of 129,358 shares, the short-interest ratio is currently 1.2 days. Currently, 4.0% of the shares of the company are short sold. Currently, 4.0% of the shares of the company are short sold. Based on an average trading volume of 129,358 shares, the short-interest ratio is currently 1.2 days.

Capstone Therapeutics Stock Performance

Shares of Capstone Therapeutics stock traded down $0.03 during trading on Monday, reaching $0.59. The company’s stock had a trading volume of 45,132 shares, compared to its average volume of 169,491. The company has a quick ratio of 0.35, a current ratio of 0.95 and a debt-to-equity ratio of 0.29. The business’s 50-day moving average price is $0.65 and its 200-day moving average price is $0.94. Capstone Therapeutics has a 52 week low of $0.49 and a 52 week high of $4.18. The firm has a market cap of $5.39 million, a PE ratio of -0.62 and a beta of -1.21.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Capstone Therapeutics currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics as of its most recent filing with the SEC. 2.55% of the stock is currently owned by hedge funds and other institutional investors.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.